Centessa Pharmaceuticals PLC
NASDAQ:CNTA

Watchlist Manager
Centessa Pharmaceuticals PLC Logo
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Watchlist
Price: 16.9 USD -3.59% Market Closed
Market Cap: 2.2B USD
Have any thoughts about
Centessa Pharmaceuticals PLC?
Write Note

Centessa Pharmaceuticals PLC
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Centessa Pharmaceuticals PLC
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash Interest Paid
$9.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Cash Interest Paid
ÂŁ15k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Cash Interest Paid
$2.1m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash Interest Paid
ÂŁ5.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash Interest Paid
ÂŁ17.3m
CAGR 3-Years
69%
CAGR 5-Years
39%
CAGR 10-Years
25%
No Stocks Found

Centessa Pharmaceuticals PLC
Glance View

Market Cap
2.2B USD
Industry
Biotechnology

In the burgeoning landscape of biopharmaceutical innovation, Centessa Pharmaceuticals PLC stands out with a distinctive operating model that seeks to streamline the path from discovery to market. Centessa, founded in 2020, uniquely consolidates a range of biotech subsidiaries, each focused on distinct therapeutic areas. This structure enables them to maintain a sharp focus on scientific discovery while sharing corporate functions like operations, finance, and legal services to maximize efficiency. By integrating these companies under a single umbrella, Centessa hopes to mitigate the typical inefficiencies and bureaucratic delays that plague the path from pipeline to patient, driving forward their goal of developing transformative medicines. With an emphasis on nimblenes and productivity, Centessa monetizes its pipeline by advancing its most promising drug candidates through clinical development stages, subsequently seeking partnerships or acquisitions with larger pharmaceutical entities. The company's revenue stream hinges on the successful development and eventual commercialization or licensing of these pioneering therapies, often focusing on complex and challenging medical conditions. By nurturing a diverse portfolio of cutting-edge research programs — spanning areas like oncology, immunology, and rare diseases — Centessa strives to deliver breakthroughs that not only enhance patient lives but also provide substantial returns on investment through strategic collaborations and licensing deals within the pharmaceutical ecosystem.

CNTA Intrinsic Value
0.46 USD
Overvaluation 97%
Intrinsic Value
Price

See Also

What is Centessa Pharmaceuticals PLC's Cash Interest Paid?
Cash Interest Paid
9.9m USD

Based on the financial report for Dec 31, 2023, Centessa Pharmaceuticals PLC's Cash Interest Paid amounts to 9.9m USD.

What is Centessa Pharmaceuticals PLC's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 1Y
36%

Over the last year, the Cash Interest Paid growth was 36%.

Back to Top